nach oben

Erschienen in:

01.03.2011 | Nephrology - Original Paper

Bone mineral density and parathyroid function in patients on maintenance hemodialysis

verfasst von: Cs. Ambrus, Cs. Almasi, K. Berta, Gy. Deak, A. Marton, M. Zs. Molnar, Zs. Nemeth, Cs. Horvath, P. Lakatos, M. Szathmari, I. Mucsi

Erschienen in: International Urology and Nephrology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

The relationship between parathyroid function, an important determinant of bone turnover, and bone mineral density (BMD) in patients with chronic kidney disease is not fully understood. We wanted to analyze the association between BMD and parathyroid function in hemodialysis patients in details.

Methods

In a cross-sectional design, data from 270 patients (age 55 ± 15 years, 60% men, all Caucasian) on maintenance hemodialysis were analyzed. All patients underwent dual energy X-ray absorptiometry of the lumbar spine (LS), femoral neck (FN) and distal radius (DR). In addition to routine laboratory tests, blood samples were collected for iPTH, serum markers of bone metabolism (alkaline phosphatase, type I collagen crosslinked-C-telopeptide) and 25OH vitamin D.

Results

Based on Z-scores, bone mineral density was moderately reduced only at the femoral neck in the total cohort. The average Z-score of the “low PTH” group (iPTH < 100 pg/ml) was not different from the Z-score of patients with iPTH in the “target range” (100–300 pg/ml) at any measurement site. While iPTH was negatively correlated with BMD at all measurement sites in patients with iPTH > 100 pg/ml (rho = −0.255, −0.278 and −0.251 for LS, FN and DR, respectively, P < 0.001 for all), BMD was independent of iPTH in patients with iPTH < 100 pg/ml. Furthermore, iPTH was not associated with serum markers of bone metabolism, but these markers were negatively correlated with BMD in the “low PTH” group.

Conclusions

Low PTH levels are not associated with low BMD in patients with end-stage kidney disease. Furthermore, bone metabolism seems to be independent of iPTH in patients with relative hypoparathyroidism likely reflecting skeletal resistance to PTH.

Moe SM et al (2007) Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis 14(1):3–12PubMedCrossRef

Moe S et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953PubMedCrossRef

Johansen KL, Chertow GM (2007) Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients. J Ren Nutr 17(5):305–313PubMedCrossRef

Mittalhenkle A, Gillen DL, Stehman-Breen CO (2004) Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis 44(4):672–679PubMed

Toussaint ND et al (2008) Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 23(2):586–593PubMedCrossRef

Ersoy FF (2007) Osteoporosis in the elderly with chronic kidney disease. Int Urol Nephrol 39(1):321–331PubMedCrossRef

Alem AM et al (2000) Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58(1):396–399PubMedCrossRef

Jadoul M et al (2006) Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney Int 70(7):1358–1366PubMedCrossRef

Urena P et al (2003) Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 18(11):2325–2331PubMedCrossRef

10.

Jamal SA, Hayden JA, Beyene J (2007) Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 49(5):674–681PubMedCrossRef

11.

Ersoy FF et al (2006) Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients. J Bone Miner Metab 24(1):79–86PubMedCrossRef

12.

Gerakis A et al (2000) Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 13(6):437–443PubMed

13.

Jamal SA et al (2002) Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis 39(4):843–849PubMedCrossRef

14.

Merino JL et al (2004) Changes in bone mineral density during the first year of dialysis treatment. Int Urol Nephrol 36(2):285–286PubMedCrossRef

15.

Cunningham J et al (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43(3):566–571PubMedCrossRef

16.

Barreto FC et al (2006) Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int 69(10):1852–1857PubMedCrossRef

17.

Martin KJ et al (2004) Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 43(3):558–565PubMedCrossRef

18.

Coco M, Rush H (2000) Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36(6):1115–1121PubMedCrossRef

19.

Danese MD et al (2006) PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47(1):149–156PubMedCrossRef

20.

Wang M et al (1995) Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26(5):836–844PubMedCrossRef

21.

Eeckhout E et al (1989) Monitoring of bone mineral content in patients on regular hemodialysis. Nephron 52(2):158–161PubMedCrossRef

22.

Lechleitner P et al (1994) Bone mineral densitometry in dialyzed patients: quantitative computed tomography versus dual photon absorptiometry. Bone 15(4):387–391PubMedCrossRef

23.

Taal MW et al (1999) Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 14(8):1922–1928PubMedCrossRef

24.

Kleinbaum DG, Kupper LL, Muller KE, Nizam A (eds) (1998) Applied regression analysis and other multivariable methods, 3rd edn. Duxbury Press, Pacific Grove, pp 281–316

25.

Atsumi K et al (1999) Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33(2):287–293PubMedCrossRef

26.

Dolgos S et al (2008) Determinants of bone mass in end-stage renal failure patients at the time of kidney transplantation. Clin Transpl 22(4):462–468CrossRef

27.

Guh JY et al (2002) Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 39(6):1245–1254PubMedCrossRef

28.

London GM et al (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transpl 18(9):1731–1740CrossRef

29.

London GM et al (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15(7):1943–1951PubMedCrossRef

30.

Spasovski GB (2007) Bone health and vascular calcification relationships in chronic kidney disease. Int Urol Nephrol 39(4):1209–1216PubMedCrossRef

31.

Torres A et al (1995) Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47(5):1434–1442PubMedCrossRef

32.

Hutchison AJ et al (1993) Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44(5):1071–1077PubMedCrossRef

33.

Gerakis A et al (1996) Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transpl 11(12):2430–2438

34.

Quarles LD, Lobaugh B, Murphy G (1992) Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75(1):145–150PubMedCrossRef

35.

Monge M et al (2006) Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. Nat Clin Pract Nephrol 2(6):326–336PubMedCrossRef

36.

Shahapuni I et al (2005) How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients? Semin Dial 18(3):226–238PubMedCrossRef

37.

Fournier A et al (1997) The clinical significance of adynamic bone disease in uremia. Adv Nephrol Necker Hosp 27:131–166PubMed

38.

Ghazali A et al (1999) Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser’s zones independent of calcitriol? Kidney Int 55(6):2169–2177PubMedCrossRef

39.

Jean G et al (2008) Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transpl 23(11):3670–3676CrossRef

40.

Ueda M et al (2005) Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci 77(10):1130–1139PubMedCrossRef

41.

Drueke TB (1996) Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. Pediatr Nephrol 10(3):348–350PubMed

42.

Urena P et al (1996) PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transpl 11(10):2008–2016

43.

Slatopolsky E et al (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58(2):753–761PubMed

44.

Lehmann G et al (2005) Specific measurement of PTH (1–84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 68(3):1206–1214PubMedCrossRef

45.

Sneve M et al (2008) The association between serum parathyroid hormone and bone mineral density, and the impact of smoking: the Tromso study. Eur J Endocrinol 158(3):401–409PubMedCrossRef

46.

Pei Y et al (1993) Renal osteodystrophy in diabetic patients. Kidney Int 44(1):159–164PubMedCrossRef

47.

van Daele PL et al (1995) Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam study. Ann Intern Med 122(6):409–414PubMed

Titel: Bone mineral density and parathyroid function in patients on maintenance hemodialysis
verfasst von: Cs. Ambrus
Cs. Almasi
K. Berta
Gy. Deak
A. Marton
M. Zs. Molnar
Zs. Nemeth
Cs. Horvath
P. Lakatos
M. Szathmari
I. Mucsi
Publikationsdatum: 01.03.2011
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 1/2011
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-009-9702-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Angiogenesis in renal cell carcinoma: correlation of microvessel density and microvessel area with other prognostic factors

Acute kidney injury secondary to renal large B-cell lymphoma: role of early renal biopsy

Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models

Cofilin-1 in the podocyte: a molecular switch for actin dynamics

Long-term outcome of penile appearance and sexual function after hypospadias repairs: situation and relation